RxSight (RXST) Stock Forecast, Price Target & Predictions
RXST Stock Forecast
RxSight stock forecast is as follows: an average price target of $68.60 (represents a 24.82% upside from RXST’s last price of $54.96) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
RXST Price Target
The average price target for RxSight (RXST) is $68.60 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $72.00 to $65.00. This represents a potential 24.82% upside from RXST's last price of $54.96.
RXST Analyst Ratings
According to 4 Wall Street analysts, RxSight's rating consensus is 'Buy'. The analyst rating breakdown for RXST stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
RxSight Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | David Saxon | Needham | $66.00 | $54.54 | 21.01% | 20.09% |
| Aug 06, 2024 | Thomas Stephan | Stifel Nicolaus | $65.00 | $40.78 | 59.39% | 18.27% |
| Aug 06, 2024 | David Saxon | Needham | $54.00 | $47.15 | 14.54% | -1.75% |
| May 07, 2024 | Steven Lichtman | Oppenheimer | $72.00 | $62.84 | 14.58% | 31.00% |
| May 07, 2024 | David Saxon | Needham | $75.00 | $62.84 | 19.35% | 36.46% |
| May 07, 2024 | Tom Stephan | Stifel Nicolaus | $75.00 | $62.84 | 19.35% | 36.46% |
| May 07, 2024 | Lawrence Biegelsen | Wells Fargo | $68.00 | $62.84 | 8.21% | 23.73% |
| May 07, 2024 | Ryan Zimmerman | BTIG | $72.00 | $62.84 | 14.58% | 31.00% |
| May 06, 2024 | Thomas Stephan | Stifel Nicolaus | $68.00 | $61.68 | 10.25% | 23.73% |
| Dec 13, 2023 | Lawrence Biegelsen | Wells Fargo | $42.00 | $39.78 | 5.58% | -23.58% |
The latest RxSight stock forecast, released on Sep 13, 2024 by David Saxon from Needham, set a price target of $66.00, which represents a 21.01% increase from the stock price at the time of the forecast ($54.54), and a 20.09% increase from RXST last price ($54.96).
RxSight Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 10 |
| Avg Price Target | $66.00 | $61.67 | $65.70 |
| Last Closing Price | $54.96 | $54.96 | $54.96 |
| Upside/Downside | 20.09% | 12.21% | 19.54% |
In the current month, the average price target of RxSight stock is $66.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 20.09% increase as opposed to RxSight's last price of $54.96. This month's average price target is up 7.02% compared to last quarter, and up 0.46% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 13, 2024 | Stifel Nicolaus | Underperform | Underperform | Hold |
| Sep 13, 2024 | Needham | Buy | Buy | Hold |
| Aug 06, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 06, 2024 | Needham | Buy | Buy | Hold |
| May 07, 2024 | Stifel Nicolaus | Buy | Buy | Hold |
| May 07, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 07, 2024 | Needham | Buy | Buy | Hold |
| May 07, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 06, 2024 | BTIG | Buy | Buy | Hold |
RxSight's last stock rating was published by Wells Fargo on Sep 13, 2024. The company gave RXST a "Buy" rating, the same as its previous rate.
RxSight Financial Forecast
RxSight Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $30.67M | $29.61M | $17.49M | $16.09M | $12.62M | $11.36M | $8.94M | $8.43M | $5.79M | $4.90M |
| Avg Forecast | $51.71M | $44.27M | $44.36M | $40.04M | $40.12M | $34.69M | $32.33M | $27.56M | $28.25M | $20.55M | $19.23M | $16.28M | $15.85M | $10.98M | $10.55M | $7.32M | $7.64M | $5.22M | $4.92M |
| High Forecast | $52.54M | $44.98M | $45.07M | $40.68M | $40.76M | $34.84M | $32.84M | $28.00M | $28.70M | $20.88M | $19.53M | $16.54M | $16.10M | $11.15M | $10.66M | $7.39M | $7.72M | $5.27M | $4.97M |
| Low Forecast | $50.62M | $43.34M | $43.42M | $39.19M | $39.27M | $34.55M | $31.64M | $26.98M | $27.65M | $20.12M | $18.82M | $15.94M | $15.51M | $10.75M | $10.42M | $7.23M | $7.54M | $5.16M | $4.86M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.49% | 1.54% | 1.07% | 1.02% | 1.15% | 1.08% | 1.22% | 1.10% | 1.11% | 1.00% |
RxSight's average Quarter revenue forecast for Dec 23 based on 4 analysts is $28.25M, with a low forecast of $27.65M, and a high forecast of $28.70M. RXST's average Quarter revenue forecast represents a -7.89% decrease compared to the company's last Quarter revenue of $30.67M (Sep 23).
RxSight EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-12.51M | $-13.63M | $-11.71M | $-14.15M | $-14.54M | $-14.55M | $-15.50M | $-13.63M | $-10.59M | $-12.87M |
| Avg Forecast | $-46.69M | $-39.98M | $-40.05M | $-36.15M | $-36.22M | $-31.32M | $-29.19M | $-24.88M | $-25.51M | $-18.56M | $-17.36M | $-14.70M | $-14.31M | $-12.65M | $-9.53M | $-15.74M | $-6.90M | $-10.00M | $-4.44M |
| High Forecast | $-45.71M | $-39.13M | $-39.21M | $-35.39M | $-35.46M | $-31.19M | $-28.57M | $-24.36M | $-24.97M | $-18.17M | $-16.99M | $-14.39M | $-14.01M | $-10.12M | $-9.41M | $-12.59M | $-6.81M | $-8.00M | $-4.38M |
| Low Forecast | $-47.44M | $-40.61M | $-40.69M | $-36.73M | $-36.80M | $-31.46M | $-29.66M | $-25.28M | $-25.91M | $-18.85M | $-17.64M | $-14.94M | $-14.54M | $-15.18M | $-9.62M | $-18.88M | $-6.97M | $-12.00M | $-4.49M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.67% | 0.78% | 0.80% | 0.99% | 1.15% | 1.53% | 0.98% | 1.98% | 1.06% | 2.90% |
undefined analysts predict RXST's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than RxSight's previous annual EBITDA (undefined) of $NaN.
RxSight Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | $-12.41M | $-13.80M | $-14.83M | $-15.61M | $-17.68M | $-17.67M | $-17.60M | $-15.73M | $-12.67M | $-13.48M |
| Avg Forecast | $-897.29K | $-4.24M | $-3.85M | $-5.56M | $-6.66M | $-8.96M | $-8.57M | $-11.32M | $-14.17M | $-16.66M | $-18.09M | $-20.38M | $-28.81M | $-15.14M | $-25.67M | $-17.87M | $-23.49M | $-11.97M | $-25.69M |
| High Forecast | $-872.66K | $-4.13M | $-3.74M | $-5.41M | $-6.48M | $-7.01M | $-8.33M | $-11.01M | $-12.59M | $-16.21M | $-17.60M | $-19.82M | $-28.02M | $-12.11M | $-25.25M | $-14.29M | $-23.11M | $-9.58M | $-25.27M |
| Low Forecast | $-915.93K | $-4.33M | $-3.93M | $-5.68M | $-6.80M | $-10.12M | $-8.75M | $-11.55M | $-15.74M | $-17.01M | $-18.47M | $-20.81M | $-29.41M | $-18.17M | $-26.01M | $-21.44M | $-23.80M | $-14.36M | $-26.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.75% | 0.76% | 0.73% | 0.54% | 1.17% | 0.69% | 0.98% | 0.67% | 1.06% | 0.52% |
RxSight's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RXST's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
RxSight SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | $19.14M | $18.24M | $16.25M | $15.73M | $14.93M | $14.39M | $13.62M | $11.62M | $9.08M | $6.50M |
| Avg Forecast | $116.94M | $100.12M | $100.31M | $90.54M | $90.72M | $78.44M | $73.10M | $62.32M | $63.88M | $46.48M | $43.48M | $36.82M | $35.84M | $10.84M | $23.86M | $16.55M | $17.28M | $11.81M | $11.12M |
| High Forecast | $118.81M | $101.72M | $101.91M | $91.99M | $92.17M | $78.80M | $74.27M | $63.32M | $64.90M | $47.22M | $44.18M | $37.41M | $36.41M | $13.01M | $24.10M | $16.72M | $17.45M | $11.93M | $11.23M |
| Low Forecast | $114.47M | $98.00M | $98.19M | $88.63M | $88.81M | $78.13M | $71.56M | $61.00M | $62.53M | $45.50M | $42.56M | $36.04M | $35.08M | $8.67M | $23.56M | $16.34M | $17.06M | $11.66M | $10.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.41% | 0.42% | 0.44% | 0.44% | 1.38% | 0.60% | 0.82% | 0.67% | 0.77% | 0.58% |
RxSight's average Quarter SG&A projection for Dec 23 is $63.88M, based on 4 Wall Street analysts, with a range of $62.53M to $64.90M. The forecast indicates a 233.70% rise compared to RXST last annual SG&A of $19.14M (Sep 23).
RxSight EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.47 | $-0.56 | $-0.64 | $-0.64 | $-0.64 | $-0.58 | $-0.68 | $-0.51 |
| Avg Forecast | $-0.02 | $-0.11 | $-0.10 | $-0.14 | $-0.17 | $-0.23 | $-0.22 | $-0.29 | $-0.37 | $-0.43 | $-0.47 | $-0.53 | $-0.75 | $-0.71 | $-0.67 | $-0.59 | $-0.61 | $-0.61 | $-0.67 |
| High Forecast | $-0.02 | $-0.11 | $-0.10 | $-0.14 | $-0.17 | $-0.18 | $-0.22 | $-0.29 | $-0.33 | $-0.42 | $-0.46 | $-0.52 | $-0.73 | $-0.69 | $-0.66 | $-0.58 | $-0.60 | $-0.60 | $-0.66 |
| Low Forecast | $-0.02 | $-0.11 | $-0.10 | $-0.15 | $-0.18 | $-0.26 | $-0.23 | $-0.30 | $-0.41 | $-0.44 | $-0.48 | $-0.54 | $-0.76 | $-0.73 | $-0.68 | $-0.60 | $-0.62 | $-0.62 | $-0.68 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.89% | 0.75% | 0.90% | 0.96% | 1.08% | 0.95% | 1.12% | 0.76% |
According to undefined Wall Street analysts, RxSight's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RXST previous annual EPS of $NaN (undefined).
RxSight Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VAPO | Vapotherm | $2.16 | $128.00 | 5825.93% | Hold |
| APYX | Apyx Medical | $1.16 | $8.50 | 632.76% | Buy |
| CVRX | CVRx | $7.85 | $15.83 | 101.66% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| FNA | Paragon 28 | $7.39 | $11.50 | 55.62% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| VREX | Varex Imaging | $11.82 | $17.00 | 43.82% | Buy |
| SIBN | SI-BONE | $15.73 | $20.00 | 27.15% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| RXST | RxSight | $54.96 | $68.60 | 24.82% | Buy |
| IRMD | IRadimed | $48.47 | $60.00 | 23.79% | Buy |
RXST Forecast FAQ
Is RxSight a good buy?
Yes, according to 4 Wall Street analysts, RxSight (RXST) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of RXST's total ratings.
What is RXST's price target?
RxSight (RXST) average price target is $68.6 with a range of $65 to $72, implying a 24.82% from its last price of $54.96. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will RxSight stock go up soon?
According to Wall Street analysts' prediction for RXST stock, the company can go up by 24.82% (from the last price of $54.96 to the average price target of $68.6), up by 31.00% based on the highest stock price target, and up by 18.27% based on the lowest stock price target.
Can RxSight stock reach $80?
RXST's average twelve months analyst stock price target of $68.6 does not support the claim that RxSight can reach $80 in the near future.
What is RxSight's current price target trend?
1 Wall Street analyst forecast a $66 price target for RxSight (RXST) this month, up 20.09% from its last price of $54.96. Compared to the last 3 and 12 months, the average price target increased by 12.21% and increased by 19.54%, respectively.
What are RxSight's analysts' financial forecasts?
RxSight's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $134.69M (high $136.45M, low $132.44M), average EBITDA is $-122M (high $-120M, low $-123M), average net income is $-35.508M (high $-32.832M, low $-37.227M), average SG&A $304.59M (high $308.56M, low $299.5M), and average EPS is $-0.923 (high $-0.854, low $-0.968). RXST's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $180.38M (high $183.26M, low $176.57M), average EBITDA is $-163M (high $-159M, low $-165M), average net income is $-14.548M (high $-14.149M, low $-14.85M), average SG&A $407.91M (high $414.43M, low $399.29M), and average EPS is $-0.378 (high $-0.368, low $-0.386).
Did the RXST's actual financial results beat the analysts' financial forecasts?
Based on RxSight's last annual report (Dec 2022), the company's revenue was $49M, beating the average analysts forecast of $44.7M by 9.64%. Apple's EBITDA was $-61.801M, beating the average prediction of $-52.221M by 18.35%. The company's net income was $-66.756M, missing the average estimation of $-87.491M by -23.70%. Apple's SG&A was $58.66M, missing the average forecast of $87.09M by -32.64%. Lastly, the company's EPS was $-2.41, missing the average prediction of $-2.723 by -11.48%. In terms of the last quarterly report (Sep 2023), RxSight's revenue was $30.67M, beating the average analysts' forecast of $20.55M by 49.21%. The company's EBITDA was $-12.512M, missing the average prediction of $-18.558M by -32.58%. RxSight's net income was $-12.415M, missing the average estimation of $-16.664M by -25.50%. The company's SG&A was $19.14M, missing the average forecast of $46.48M by -58.81%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.433 by -99.93%